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Abstract: Vasomotor symptoms (VMS), including hot flashes and night sweats, occur in as
many as 68.5% of women as a result of menopause. While the median duration of these symptoms
is 4 years, approximately 10% of women continue to experience VMS as many as 12 years
after their final menstrual period. As such, VMS have a significant impact on the quality of
life and overall physical health of women experiencing VMS, leading to their pursuance of
treatment to alleviate these symptoms. Management of VMS includes lifestyle modifications,
some herbal and vitamin supplements, hormonal therapies including estrogen and tibolone,
and nonhormonal therapies including clonidine, gabapentin, and some of the serotonin and
serotonin–norepinephrine reuptake inhibitors. The latter agents, including desvenlafaxine, have
been the focus of increased research as more is discovered about the roles of serotonin and
norepinephrine in the thermoregulatory control system. This review will include an overview
of VMS as they relate to menopause. It will discuss the risk factors for VMS as well as the
proposed pathophysiology behind their occurrence. The variety of treatment options for VMS
will be discussed. Focus will be given to the role of desvenlafaxine as a treatment option for
VMS management.
Keywords: menopause, vasomotor symptoms, hot flashes, vasomotor symptom treatment,
desvenlafaxine
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The final menstrual period (FMP) marks the point in time between the menopausal
transition and postmenopause.1 Natural menopause, specifically, is confirmed after 12
consecutive months of amenorrhea in the absence of any obvious, pathologic cause.2
These 12 months of amenorrhea, inclusive, characterize a woman as postmenopausal.1
This can further be divided into early postmenopause (1–4 years after the FMP) and
late postmenopause (.5 years since the FMP).1,3 Surgical menopause results following
surgical removal of the ovaries. In either instance, one result of the declining estrogen
concentrations is the occurrence of vasomotor symptoms (VMS) that include hot
flashes and night sweats.
VMS of any degree, mild to severe, are experienced by 58.9% of Latin American
women at perimenopause, the years immediately surrounding the FMP.3 The peak
incidence of VMS is noted to occur in American women 1 year after the FMP,4 and
68.5% of women experience VMS of some degree in early menopause, which is
described as 1–5 years after the FMP.3 Further, the median duration of VMS occurrence
is 4 years, while approximately 10% of women experience VMS as long as 12 years
after the FMP.4
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Severe VMS occurs in 10.8% of women in the
perimenopausal time frame, in 12.3% of women during
early menopause, and in 11.5% of women in late menopause,
def ined as greater than 5 years from the FMP. 3 The
prevalence and severity of VMS is greater in women who
are surgically menopausal compared to women experiencing
natural menopause.3 Given the overall frequency of these
symptoms, it is important to be aware of the risk factors for
their occurrence such that if the risk factor(s) are modifiable,
the risk of VMS could be reduced. Further, awareness of risk
may help to identify those women who may be in greatest
need of VMS treatment as a means to improve quality of life
(QOL) and overall health.

VMS risk factors
Several risk factors for the occurrence and severity of VMS
have been established.5–7 Obesity, race, and smoking have
been most closely associated with the occurrence of VMS.
Various reports of the linkage between obesity and VMS
include the fact that VMS were observed to be absent or
infrequent in a population of women with a mean body mass
index (BMI) of 28 kg/m2 while women with an average BMI
of 31 kg/m2 were more likely to report VMS as occurring
more frequently than their lower-BMI counterparts. 5
Further, Gold and colleagues discovered similar findings
as the frequency of VMS was statistically associated with
the woman’s BMI (P , 0.0001); the average BMI for
women experiencing no VMS or symptoms for ,6 days
in the 2 weeks prior to evaluation was 28 kg/m2, while the
average BMI for women experiencing VMS $ 6 days in
the prior 2 weeks was 30.9 kg/m.2,6 Specifically, another
study established a sevenfold greater risk for being in the
highest quartile of having the most bothersome VMS for
every 2.7 kg/m2 increase in BMI.7 While the physiologic
relationship between BMI and VMS frequency and severity
is not completely understood, it is thought to be linked to
the role of adipose tissue as an insulator that prevents the
release of heat.5
Race and ethnic variations are also associated with
differences in the incidence of VMS. One study established
that the frequency of VMS is significantly greater among
African American women compared to women of other races
(P , 0.01).6 While the exact reason for this is unknown, this
population of women has been observed to have the highest
BMIs and highest rates of current smoking and exposure to
tobacco smoke. Further, African American women have been
observed to exhibit a different perception and tolerance
of VMS compared to other racial and ethnic populations.
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Another study confirmed this finding in African American
women when it reported that they are most likely to report
and describe their VMS as bothersome.5 Caucasian and
Hispanic women report VMS as often as African American
women, but do not report them to be as severe. Chinese and
Japanese women are the least likely to report VMS or to
describe them as bothersome.5 Overall, variability among
different cultures may be related to variability (by culture)
of other determinants of VMS, such as hormone use, age,
BMI, depression, anxiety, poor physical health, perceived
stress, cigarette smoking (and exposure to passive smoke),
and acculturation.8
A link between cigarette smoking as well as passive
exposure to tobacco smoke and the occurrence of VMS has
been hypothesized to exist, as cigarette smoking may exhibit
antiestrogenic effects. Study findings have illustrated that
smokers are 60% more likely to report any VMS compared
to nonsmokers.5 Additionally, the frequency of VMS is
associated with current smoking; the odds ratio for smokers
reporting VMS being 1.63 (range 1.25–2.12; P , 0.01)
compared to nonsmokers.6
Other risk factors for VMS that have been identified but
for which the data are limited include physical inactivity,
the presence of negative affect or anxiety, and educational
status. The associations between physical inactivity and VMS
have been studied and described as weak.5 While anxiety and
negative affect have been associated with VMS occurrence
and frequency as well as an increased likelihood of the VMS
being described as bothersome,5 these findings have not
been studied extensively. In fact, it is difficult to reach any
conclusion using the available studies that would be applicable
to practice, as the studies utilized poor, largely nonvalidated
measures of said symptoms.9 Similarly, an association
between VMS and level of education has been observed.
VMS reports have been observed to be higher among women
with some college education compared to women with high
school as their terminal level of education increases.6 This
has not been replicated or reported elsewhere.

Impact of VMS on quality of life
VMS negatively affect QOL,3,5 and this has been evaluated
globally as well as specifically for its impact on the factors
contributing to QOL. These factors include sexual function,
sleep quality, mood, and cognitive function.
The poorest health-related QOL has been observed among
women with the most frequent VMS.5 More precisely, when
comparing women who experience VMS to those in whom
VMS are absent, any degree of VMS is associated with
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nearly a fivefold higher risk for severe QOL impairment;
severe VMS are associated with a 20-fold higher risk for
severe QOL impairment (P = 0.0001 for both compared to
absent VMS).3 Women experiencing any degree of VMS
are at an increased risk of experiencing other menopausal
symptoms when compared to women who do not have VMS.
Specifically, in women who experience VMS, 62% of them
also experience sexual disturbances, 74% suffer from sleep
disturbances, 76% note the occurrence of depressed mood,
and 78% experience increased mental exhaustion. These
menopausal symptoms occur in 29%, 41%, 42%, and 49%
of women without VMS, respectively.3 Further, Thurston and
Joffe’s findings also concluded that the presence of VMS is
associated with all aspects of sleep disturbances including
poor continuity and quality and early morning awakening.5

VMS pathophysiology
VMS are theorized to result from dysfunction in the woman’s
“tightly controlled temperature circuitry,” leading to
exaggerated activation of heat-dissipation responses such as
peripheral vasodilation and sweating.10 The thermoregulatory
circuitry includes the brain, internal body cavity, and the
peripheral vasculature. It is thought that this circuitry
functions under the influence of consistent concentrations of
the neurotransmitters serotonin and norepinephrine.
Changes in gonadal hormones, notably estrogen,
have been associated with fluctuations in serotonin and
norepinephrine. The occurrence of VMS with the fluctuating
levels of estrogen observed during perimenopause and the
further declining levels of estrogen as occurs after menopause
is likely influenced by the resultant fluctuating levels of
serotonin and norepinephrine, contributing to disruption of the
thermoregulatory circuitry.10 Specifically, reduced estrogen
concentrations within the hypothalamic temperatures center

negatively affect serotonin and norepinephrine concentrations
in this location and contribute significantly to the occurrence
of VMS.11 Temperature information is processed within the
anterior hypothalamus in the preoptic area (POA), where it
is felt that heat-sensitive neurons control the release of heat.11
Serotonergic neurons and noradrenergic pathways have both
been identified as projecting into the POA. As the POA is
directly related to temperature control and under the influence
of serotonin and norepinephrine, the fluctuating estrogen
concentrations that exist with menopause lead to VMS.
Given the data linking estrogen fluctuations to a reduction
of serotonin and norepinephrine, it has been postulated that
pharmacologic agents such as serotonin reuptake inhibitors
and serotonin–norepinephrine reuptake inhibitors may help
to reestablish levels of these neurochemicals within the thermoregulatory centers, reducing the occurrence of VMS.10,11

VMS treatment
Nonpharmacologic
Many nonpharmacologic treatments have been identified to
treat VMS. These include but are not limited to acupuncture, hypnosis, and lifestyle changes. The overall evidence
supporting these treatments is variable. See Table 1 for a
list of potential nonpharmacologic treatment options and a
summary of the evidence available for each.

Pharmacologic
Herbals/vitamins

A variety of herbal medications and vitamin supplements
have been studied for the treatment of VMS associated with
menopause, including black cohosh, dehydroepiandrosterone,
evening primrose oil, phytoestrogens, and vitamin E. Similar
to the findings for the nonpharmacologic interventions for
VMS, the efficacy findings for herbal medications and

Table 1 Nonpharmacologic treatments for vasomotor symptoms (VMS)12–18
Nonpharmacologic
treatment

Evidence

Acupuncture

• A randomized clinical trial illustrated that acupuncture was as effective as venlafaxine at reducing hot flushes.12
• Another study and review have shown a significant reduction in the mean number of hot flushes with acupuncture
compared to placebo.13,14
• Two small studies in breast cancer patients showed that hypnosis was more effective at reducing vasomotor
symptoms (VMS) compared to no treatment.15,16
• Studies have shown that keeping cool by using layered clothing, cooler room temperatures, drinking cool liquids, and
avoiding triggers such as hot/spicy food can help with the severity of hot flushes.17
• Studies regarding the efficacy of exercise in relieving VMS are ongoing;18 however, at this time there is an overall
lack of randomized controlled clinical trials.
• Clinical trials evaluating the effect of weight loss on VMS are lacking.
• Many researchers believe smoking cessation can help reduce vasomotor symptoms, although evidence in this area is
lacking, as there are currently no clinical trials evaluating this idea.

Hypnosis
Lifestyle changes
• Layered clothing
• Cool atmosphere
• Cool drinks
• Avoiding hot/spicy food
• Exercise/weight loss
• Smoking cessation

International Journal of Women’s Health 2012:4

submit your manuscript | www.dovepress.com

Dovepress

307

Dovepress

Umland and Falconieri

vitamin supplements are also inconsistent.19 Further, the longterm safety of these products is unclear.19 Table 2 depicts
the various herbal medications and vitamins that have been
examined for menopausal-related VMS, including a review
of the efficacy and safety information available for each.

Hormone therapy
Estrogen replacement

Hormone replacement therapy remains the most effective
treatment for VMS. According to the most recent Cochrane
review, hormone therapy reduces the frequency and severity
of hot flashes by 75%–79%.36 There are numerous estrogen
and estrogen–progestin combination products available for
women to use. Studies have shown hormone therapy to be
well tolerated, with the most common side effects including
breast tenderness, headache, and uterine bleeding.
Although hormone therapy is effective for the treatment of VMS, results from the Women’s Health Initiative
(WHI) demonstrate that hormone replacement therapy may
have negative effects on breast tissue, as its use has been
associated with an increased risk of breast cancer.37 The
WHI also shows that unopposed estrogen therapy is associated with an increased risk of endometrial cancer.37 The
WHI has also shown that hormone replacement therapy is

associated with an increased risk of cardiovascular disease.
Since the WHI report, women have become more apprehensive regarding the use of hormone replacement therapy
due to these safety concerns. Current recommendations are
to use hormone replacement therapy at the lowest effective
dose for the shortest duration of time.2 Because of these
findings and the reaction of women towards them, there
has been increased demand for alternative medications to
treat VMS.

Tibolone
Tibolone is another option for the treatment of VMS. It is
available in Europe, Canada, and some other countries in
Latin America and Asia; it is not approved in the United
States. Tibolone is a synthetic drug, and its metabolites have
properties similar to estrogen, androgen, and progesterone.38
Compared to hormone replacement therapy, studies have
found that there is a lower incidence of uterine bleeding
with tibolone.38 Relative to VMS, most studies show that its
efficacy is comparable to hormone replacement therapy.39
However, its use carries similar risks to hormone replacement
therapy in breast and endometrial tissues. A number of studies
have indicated that tibolone may increase the risk of breast
cancer and endometrial hyperplasia.38,40,41 For these reasons,

Table 2 Herbals and vitamins for the treatment of vasomotor symptoms (VMS)20–35
Herbal/vitamin

Efficacy/safety information

Black cohosh

• Two meta-analyses showed black cohosh to have some benefit in treating VMS.20,21
• One randomized trial showed black cohosh to have similar efficacy to tibolone at reducing VMS, as
measured by the Kupperman Menopause Index.22
• One meta-analysis and another randomized controlled trial have shown no benefit to treatment with
black cohosh.22,24
• Long-term effects are unknown, and there exists a possibility of hepatotoxicity.20,21 However, a recent
meta-analysis of five studies (two had a duration of 12 weeks, two had a duration of 16 weeks, and one
had a duration of 24 weeks) showed that black cohosh does not negatively impact liver function.25
• The overall long-term efficacy and safety data for black cohosh remain unclear.
• A randomized controlled trial showed that the combination of these herbals significantly improved VMS
and symptoms of depression as measured by the Menopause Rating Scale and Hamilton Depression
Rating Scale, respectively, compared with placebo.26
• A small study has shown a reduction in the frequency of hot flushes in patients taking DHEA supplements.27
• Larger randomized trials are needed to further evaluate these findings.
• Randomized trials have not shown any benefit in the frequency of hot flushes with evening primrose oil.28
• One clinical trial and two meta-analyses do not support the use of soy for vasomotor symptoms.29–31
• A very recent meta-analysis of 17 trials found soy isoflavone supplements to be significantly more
effective than placebo at reducing the frequency and severity of hot flashes.32
• A recent meta-analysis and randomized clinical trial concluded there was no impact on the incidence and
severity of hot flushes with red clover.30,33
• Flaxseed, which is very high in lignan, has been studied for the treatment of hot flushes and has been
shown to successfully reduce VMS.34
• A randomized clinical trial showed that Vitamin E reduced the occurrence of hot flashes by about one
per day;35 however, it was not preferred by patients over placebo.
• Not recommended at this time due to clinically insignificant effects.

Black cohosh with St John’s wort

Dehydroepiandrosterone (DHEA)
Evening primrose oil
Phytoestrogens
• Isoflavones
• Soy
• Red clover
• Lignan

Vitamin E
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tibolone may not be any safer than hormone replacement
therapy itself.

Tissue-selective estrogen complexes
A new hormone therapy being developed in the US is tissueselective estrogen complexes. This therapy combines a
selective estrogen receptor modulator (SERM) with estrogen.
SERMs act as agonists or antagonists in different tissues,
and each SERM has a distinct profile of action. With the
appropriate SERM in place, estrogen’s negative effects are
blocked in breast and endometrial tissues. This allows the
estrogen to impart its positive effects on bone and vaginal
tissue as well as reduce VMS.42
Currently, the SERM bazedoxifene, which is an
agonist in the bone and an antagonist in the breast and
uterus, is being studied in combination with estrogen for
the treatment of menopausal symptoms. The Phase III
SMART-1 (Selective estrogens, Menopause and Response
to Therapy) trial demonstrated that the combination of
estrogen and bazedoxifene significantly reduces hot flashes
at most time points, with higher doses of bazedoxifene being
more effective.43 The results also show that there is a very
low incidence of endometrial hyperplasia after 2 years of
treatment. More randomized controlled trials are underway
to assess the long-term effect of this combination therapy on
the bone and breast. Nevertheless, tissue-selective estrogen
complexes have the possibility of providing comparable
efficacy to hormone replacement therapy with an improved
safety and tolerability profile.

Nonhormone therapies
Clonidine
A number of double-blind, controlled trials have evaluated
the efficacy of clonidine for VMS.44,45 One trial studied
the clonidine patch versus placebo in 110 women with a
history of breast cancer and found that clonidine reduces the
frequency of hot flashes by 20% at 4 weeks (P , 0.001).44
Another study evaluated 149 postmenopausal women over
8 weeks and found a decrease in hot-flash frequency of 38%
in the clonidine group versus a 24% reduction in placebo
(P = 0.006).45 Both of these trials did show that clonidine is
associated with considerable adverse effects, including dry
mouth, constipation, and drowsiness.44,45 Based on a recent
meta-analysis, the results of these trials have been rather
inconsistent regarding the efficacy of clonidine in VMS.30
Half of the trials included in this meta-analysis show that
clonidine significantly reduces VMS frequency compared to
placebo, while the other half of the trials show no significant
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difference. With its inconsistent efficacy data and substantial
adverse effects, clonidine is not an ideal choice for VMS
treatment.

Gabapentin
Multiple randomized controlled trials evaluating the efficacy
of gabapentin for the treatment of VMS show that gabapentin
can successfully reduce VMS frequency compared to
placebo.46,47 One trial involving 59 postmenopausal women
compared 900 mg/day gabapentin versus placebo and
found a 45% reduction in the gabapentin group versus
29% in the placebo group at week 12 (P = 0.02).46 A larger
trial involving 420 women with breast cancer evaluated
gabapentin 300 mg/day, 900 mg/day, and placebo.47 The
study showed a 49% reduction in hot-flash severity scores at
week 8 in the 900-mg group, a 33% reduction in the 300-mg
group, and a 21% reduction in the placebo group (P = 0.007
for all comparisons). 47 A randomized control trial of
60 postmenopausal women comparing gabapentin titrated up
to 2400 mg/day, estrogen therapy, and placebo showed that
gabapentin reduced the frequency of VMS by 71%, compared
to 72% in the estrogen group and 54% in the placebo group
at week 12 (P = 0.04 for gabapentin compared to placebo;
no significant difference between gabapentin and estrogen).48
Larger and longer trials are warranted to further examine the
efficacy and safety of gabapentin for treating VMS.

Pregabalin
Pregabalin is currently indicated for the treatment of fibromyalgia, partial-onset seizures, postherpetic neuralgia, and
pain associated with diabetic neuropathy. Chemically, it is
similar to gabapentin, and for that reason, its use in treating
VMS is being evaluated.49 Results of a Phase III randomized
trial involving 163 postmenopausal women over 6 weeks
demonstrated that pregabalin at doses of 75 mg twice daily
and 150 mg twice daily reduced hot-flash scores by 65%
and 71%, respectively, compared to only 50% in the placebo
group (P = 0.009 and P = 0.007, respectively).50 Larger,
longer-term trials are needed to confirm these results.

Selective serotonin reuptake inhibitors/
serotonin–norepinephrine reuptake
inhibitors
The selective serotonin reuptake inhibitors (SSRIs), such
as citalopram, escitalopram, fluoxetine, paroxetine, and
sertraline, and the serotonin–norepinephrine reuptake
inhibitors (SNRIs), such as duloxetine, venlafaxine,
and desvenlafaxine, have been investigated for the
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treatment of VMS. Two randomized controlled trials have
shown that paroxetine reduces symptoms of VMS.51,52 In
one study, 156 menopausal women received paroxetine
12.5 mg/day, 25 mg/day, or placebo. The study demonstrated
a 62% reduction in hot-flash score at 6 weeks in the 12.5-mg
group, a 65% reduction in the 25-mg group, and a 38% reduction in the placebo group (P = 0.03 and P = 0.007 vs placebo,
respectively).51 In another study, 151 postmenopausal women
received 4 weeks of paroxetine 10 mg/day, paroxetine
20 mg/day, or placebo. Results showed the 10-mg group
reduced the hot-flash severity score by 40.6% compared to
the 13.7% reduction in the placebo group (P = 0.006), while
the 20-mg group reduced hot-flash severity score by 51.7%,
compared to 26.6% for the placebo comparator (P = 0.002).52
Randomized trials have shown that citalopram, escitalopram,
and fluoxetine are also effective at reducing the frequency of
hot flashes. In a trial evaluating citalopram, 254 postmenopausal women received citalopram 10 mg/day, citalopram
20 mg/day, citalopram 30 mg/day, or placebo. 53 After
6 weeks, there was a mean reduction in hot-flash severity
score of 49% in the 10-mg group, 50% in the 20-mg group,
and 55% in the 30-mg group compared to 23% in the placebo
group (P , 0.002 for all comparisons).53 A recent randomized
double-blind placebo-controlled trial evaluated escitalopram
for vasomotor symptoms. The trial enrolled 205 postmenopausal women that were randomized to escitalopram
10–20 mg/day or placebo for 8 weeks. The results showed
women in the escitalopram group experienced a significant
reduction in hot-flash frequency (P , 0.001) and hot-flash
severity score (P , 0.001).54 In a trial studying fluoxetine,
81 postmenopausal women were randomized to fluoxetine
20 mg/day or placebo for 4 weeks and then crossed over to the
other treatment arm.55 In the first part of the trial, the 20-mg
group reduced hot-flash scores by 50% compared to only
36% in the placebo group (P = 0.35), but after the crossover
the reduction in hot flash scores was significant (24% vs
19%, respectively, P = 0.02).55 Other trials have evaluated
the efficacy of sertraline for the treatment of vasomotor
symptoms. In one double-blind crossover study evaluating
sertraline, 62 breast cancer survivors receiving tamoxifen
were randomized to 50 mg sertraline or placebo.56 The results
showed women taking sertraline for 6 weeks had a significant
reduction in hot-flash score compared to placebo (P = 0.03).56
Another double-blind crossover study of 102 women found
that women experienced five fewer hot flashes per week while
taking sertraline 50 mg versus placebo (P , 0.002); however,
the severity of the hot flashes was not significantly different
between sertraline and placebo.57 Most of the trials evaluating
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SSRIs have been relatively small and short in duration, and
larger and longer trials are warranted. Overall, SSRIs appear
to be effective in reducing VMS.
One very small trial has evaluated the SNRI duloxetine with
favorable outcomes. In an open-label trial, 20 postmenopausal
women with major depressive disorder were given duloxetine
at 60–120 mg/day. At the end of 8 weeks, the women showed
a significant improvement in the Montgomery–Asberg
Depression Rating Scale score from baseline (P , 0.001).58
Trials evaluating the SNRI venlafaxine for VMS have yielded
positive results, showing an approximate 55% reduction
in VMS.59,60 In one study, 191 postmenopausal women
were assigned to placebo or to target venlafaxine doses of
37.5 mg/day, 75 mg/day, or 150 mg/day. Hot-flash scores
reduced from baseline by 27% in the placebo group, 37% in
the 37.5-mg group, 61% in the 75-mg group, and 61% in the
150-mg group after 4 weeks (P , 0.0001 for all comparisons
vs placebo).59 This study demonstrated that higher doses
of venlafaxine did not correlate with improved efficacy;
however, the 150-mg dose had significantly more side effects
compared to placebo (P , 0.05), including dry mouth,
decreased appetite, nausea, and constipation.59 Another
trial of 109 postmenopausal women compared venlafaxine
at a dose of 75 mg/day to a single injection of 400 mg of
depomedroxyprogesterone acetate (DMPA).60 There was a
55% reduction in hot-flash score in the venlafaxine group,
versus a 79% reduction in the DMPA group after 6 weeks
of treatment (P , 0.001).60 Although venlafaxine does not
appear to be superior to hormone replacement therapy,
it is still a good option for the treatment of vasomotor
symptoms.
Desvenlafaxine is the major active metabolite of venlafaxine, and therefore it has been postulated that desvenlafaxine may be effective at reducing VMS frequency and severity.
In a study that evaluated the effects of desvenlafaxine on
temperature regulation in ovariectomized rats, desvenlafaxine significantly increased serotonin and norepinephrine
levels in areas of the hypothalamus that are important for
temperature homeostasis.61 Therefore, it is hypothesized that
desvenlafaxine would be effective in treating VMS caused by
temperature dysregulation in the hypothalamus, specifically
for VMS associated with menopause.

Desvenlafaxine clinical trials
To date, four clinical trials have evaluated desvenlafaxine’s
efficacy in treating VMS in postmenopausal women.62–65 In
Speroff and colleagues, 707 postmenopausal women were
assigned to desvenlafaxine 50, 100, 150, or 200 mg/day
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or placebo and evaluated over 12 weeks.62 In one trial
by Archer and colleagues, 484 postmenopausal women
received desvenlafaxine 100 mg/day, 150 mg/day, or placebo
for 12 weeks.63 In another trial conducted by Archer and
colleagues, 458 postmenopausal women were assigned to
desvenlafaxine 100 mg/day, 150 mg/day, or placebo for
12 weeks.64 Finally, in a trial conducted by Bouchard and
colleagues, 485 women received desvenlafaxine 100 mg/day,
tibolone 2.5 mg/day, or placebo for 12 weeks.65 The inclusion
and exclusion criteria of the four trials were similar. Women
must have been postmenopausal, generally healthy, have a
BMI , 40 kg/m2 (,34 kg/m2 for the Bouchard et al trial65),
and have reported a specific quantity of moderate to severe
hot flashes (seven per day or 50 per week). Women who
had recently received hormone therapy or any medications
thought to treat VMS, having a history of seizure disorder,
myocardial infarction, or malignancy, or having hepatic
dysfunction, renal dysfunction, a psychiatric disorder, or any
other major medical disease were excluded. No significant
differences were observed between the treatment groups
with regard to the baseline demographics in these trials. The
majority of patients in each of these trials were of Caucasian
descent (80%–90%). Table 3 describes the design, primary
and secondary end points, and results for each of these
clinical trials.

Efficacy results – primary end points
The four clinical trials evaluating desvenlafaxine for the
treatment of menopause-related VMS used two common
primary end points: the change in the daily frequency of
moderate-to-severe hot flashes and the change in the daily
average hot-flash severity score.62–65 In three of the trials,
the change in the daily average hot-flash severity score was
calculated as: ([number of mild hot flashes × 1] + [number
of moderate not flashes × 2] + [number of severe hot
flashes × 3])/total number of hot flashes on that day.62,63,65
In the fourth clinical trial, the procedure for calculating
the average daily hot-flash severity score was not clearly
defined.64
In both studies conducted by Archer and colleagues,
the 100-mg/day and 150-mg/day doses of desvenlafaxine
were superior to placebo at reducing the number of
moderate-to-severe hot flashes at weeks 4 and 12.63,64 In
these two studies, both desvenlafaxine groups experienced
a reduction in the frequency of moderate-to-severe hot
flashes by 60%–66%. In one Archer trial, the desvenlafaxine
100-mg group and 150-mg group differed significantly from
placebo at weeks 4 and 12 (P , 0.002 at week 4 for both
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groups; P , 0.001 at week 12 for both groups).63 In the other
Archer trial, the desvenlafaxine 100-mg group and 150-mg
group also differed significantly from placebo at weeks 4
and 12 (P # 0.012 for both groups at week 4, P , 0.005 for
the 100-mg group, and P , 0.012 for the 150-mg group at
week 12).64 In the trial conducted by Speroff and colleagues,
desvenlafaxine doses of 100 mg/day and 150 mg/day significantly reduced the average daily number of moderateto-severe hot flashes compared with placebo at week 12
by 60%–64% (P = 0.005 and P = 0.02, respectively).62
However, in this trial, the results for the desvenlafaxine
150-mg group did not differ significantly from placebo at
week 4, and the desvenlafaxine 50-mg and 200-mg groups
did not differ significantly from placebo at either week 4 or
12. In contrast, Bouchard and colleagues observed that the
average daily number of moderate-to-severe hot flashes was
not significantly different for the desvenlafaxine group at
weeks 4 and 12 compared to placebo: desvenlafaxine reduced
the average number of hot flashes by 57.7%, while placebo
reduced the average number of hot flashes by 57.5% at week
12.65 Tibolone reduced the average number of hot flashes by
81% and differed significantly from placebo at weeks 4 and
12 (P , 0.001 for all comparisons).65
In both studies by Archer and colleagues, the average
daily hot-flash severity score differed significantly for both
the desvenlafaxine 100-mg and 150-mg groups compared to
placebo at weeks 4 and 12 (P # 0.005 at both time points;63
P # 0.025 at both time points64). In the study by Speroff and
colleagues, the 100-mg and 200-mg desvenlafaxine groups
differed from placebo at week 12 in terms of the average
daily severity score (P = 0.002 and P = 0.013, respectively),
but not at week 4.62 However, the desvenlafaxine 50-mg and
150-mg groups were not significantly different from placebo
at week 4 or 12. In the study by Bouchard and colleagues, the
average daily hot-flash severity score was not significantly
different between the desvenlafaxine 100-mg group and
placebo groups at weeks 4 and 12; however, the tibolone
2.5-mg group was significantly different from placebo at both
of these time points (P , 0.001 for both comparisons).65

Efficacy results – secondary endpoints
Important secondary endpoints of the trials included the
proportion of patients achieving a 50% and 75% reduction
in the number of hot flashes and the number of nighttime
awakenings attributed to hot flashes.
The proportion of patients achieving at least a 50%
or 75% reduction in the number of hot flashes was
significantly different between placebo and the 100-mg
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Archer
et al63

Speroff
et al62

Clinical
trial

• 26-week, double-blind, placebo-controlled trial
• n = 567 post-menopausal women
• 484 women included in modified ITT analysis
• Treatment groups:
   – Desvenlafaxine 100 or 150 mg/day
   – Placebo
• No dose titration used

• 52-week, multicenter, randomized,
double-blind, placebo-controlled trial
• n = 707 postmenopausal women
• 620 women included in modified ITT analysis
• Treatment groups (assigned in a 2:2:2:2:1 ratio):
   – Desvenlafaxine 50, 100, 150, or 200 mg/day
   – Placebo
• No dose-titration used

Trial design

• Change from baseline in average daily
number of moderate-to-severe hot flashes
compared with placebo at weeks 4 and 12
• Change from baseline in average daily
hot-flash severity score compared
with placebo at weeks 4 and 12
• Reduction in number of moderate and
severe hot flashes of at least 50% and
75% from baseline compared to placebo

• Change from baseline in daily number
of moderate-to-severe hot flashes
compared with placebo at weeks 4 and 12
• Change from baseline in average daily
hot flash severity score compared with
placebo at weeks 4 and 12
• Proportion of women achieving at least
a 50% or 75% reduction from baseline in
number of hot flashes at weeks 4 and 12
• Change from baseline in daily number of
nighttime awakenings due to hot flashes
at weeks 4 and 12

Primary and
secondary outcomes

Table 3 Clinical trials focusing on the efficacy of desvenlafaxine in vasomotor symptoms62–65

• Reductions in average daily number
of moderate-to-severe hot flashes
from baseline:
– Placebo: 47% at week 12
– Desvenlafaxine 100 mg:
60% at week 12 (P , 0.002 vs
placebo at week 4; P , 0.001
at week 12)

• Reductions in average daily number
of moderate-to-severe hot flashes
from baseline:
– Placebo: 51% at week 12
– Desvenlafaxine 50 mg: P = NS vs
placebo at weeks 4 and 12
– Desvenlafaxine 100 mg: 64% at
week 12 (P = 0.005 vs placebo
at week 12; P = 0.013 vs placebo
at week 4)
– Desvenlafaxine 150 mg: 60% at week
12 (P = 0.02 vs placebo at week 12;
P = NS vs placebo at week 4)
– Desvenlafaxine 200 mg: P = NS vs
placebo at weeks 4 and 12
• Moderate-to-severe reductions
in average daily hot-flash severity score
– Placebo: 18% at week 12
– Desvenlafaxine 50 mg: P = NS vs
placebo at weeks 4 and 12
– Desvenlafaxine 100 mg:
31% at week 12 (P = 0.002 vs
placebo at week 12; P = NS vs
placebo at week 4)
– Desvenlafaxine 150 mg: P = NS vs
placebo at weeks 4 and 12
– Desvenlafaxine 200 mg:
27% at week 12 (P = 0.013 vs
placebo at week 12; P = NS vs
placebo at week 4)

Primary results

• Proportion of patients achieving at
least a 75% reduction from baseline in
number of hot flashes (results for the
50% reduction were not reported)
– Placebo: 18.2% at week 4,
28.6% at week 12
– Desvenlafaxine 50 mg: P = NS vs
placebo at weeks 4 and 12
– Desvenlafaxine 100 mg:
36.6% (P = 0.005) vs placebo
at week 4; 49.7% (P = 0.003) vs
placebo at week 12
– Desvenlafaxine 150 mg:
38% (P = 0.003) vs placebo at
week 4;  P = NS vs placebo at
week 12
– Desvenlafaxine 200 mg:
33.3% (P = 0.021) vs placebo
at week 4; 45% (P = 0.022) vs
placebo at week 12
• Reductions in the daily number of
nighttime awakenings versus placebo
at week 12 (results from week 4
were not reported)
– Placebo: –2.21
– Desvenlafaxine 50 mg: –2.30 (P = NS)
– Desvenlafaxine 100 mg:
–2.77 (P = 0.013)
– Desvenlafaxine 150 mg:
–2.69 (P = 0.034)
– Desvenlafaxine 200 mg:
–2.68 (P = 0.043)
• Significantly greater percentage of
women in desvenlafaxine 100-mg
and 150-mg groups had at least a
50% and 75% reduction in number
of moderate and severe hot flashes
compared to placebo group at
weeks 4 and 12 (P # 0.004 for all
comparisons; actual percentages
not given)

Secondary results

Umland and Falconieri
Dovepress
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Bouchard
et al65

Archer
et al64

• 12-week, multicenter, randomized,
double-blind, placebo- and active-controlled trial
• n = 485 postmenopausal women
• 451 women included in modified ITT analysis
• Treatment groups:
   – Desvenlafaxine 100 mg/day
   – Tibolone 2.5 mg/day

• 12-week, double-blind, placebo-controlled trial
• n = 458 postmenopausal women
• 452 included in the modified ITT analysis
• Treatment groups:
   – Desvenlafaxine 100 or 150 mg/day
   – Placebo
• Dose titration used

• Change from baseline in average daily
number of moderate and severe hot
flashes compared to placebo
at weeks 4 and 12
• Reduction in the average daily severity
of hot flashes at weeks 4 and 12

• Change from baseline in average daily
number of moderate-to-severe hot
flashes compared to placebo
at weeks 4 and 12
• Change from baseline in average daily
hot-flash severity score compared with
placebo at weeks 4 and 12
• Reduction in number of moderate and
severe hot flashes of at least 50% and
75% from baseline
• Change from baseline in number of
nighttime awakenings attributed to
hot flashes at weeks 4 and 12

• Change from baseline in the number of
nighttime awakenings due to hot flashes
compared to placebo at weeks 4 and 12

• Reductions in average daily number
of moderate and severe hot flashes
from baseline:
– Placebo: 57.5% at week 12
– Desvenlafaxine: 57.7% at week 12
(P = NS vs placebo at weeks 4
and 12)

– Desvenlafaxine 150 mg: 66% at
week 12 (P , 0.002 vs placebo at
week 4; P , 0.001 at week 12)
• Reductions in average daily hot-flash
severity score at week 12:
– Placebo: 13%
– Desvenlafaxine 100 mg:
24% (P , 0.001 vs placebo)
– Desvenlafaxine 150 mg:
29% (P , 0.001 vs placebo)
• Reduction in the average hot flash
severity score was significant at
week 4 in both desvenlafaxine
100-mg and 150-mg groups
(P , 0.005 for both comparisons;
actual percentages not given)
• Reductions in average daily number
of moderate-to-severe hot flashes
from baseline versus placebo:
– Placebo: 50.8% at week 12
– Desvenlafaxine 100 mg:
no percentage given at week 4
(P , 0.012); 65.4% at week 12
(P , 0.005)
– Desvenlafaxine 150 mg:
no percentage given at week 4
(P , 0.012); 66.6% at week 12
(P , 0.012)
• Average daily hot-flash severity
scores were reduced significantly
from baseline for both desvenlafaxine
groups compared with placebo at
weeks 4 and 12 (P , 0.001 for
all comparisons)
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(Continued)

• S ignificantly greater percentage of
women in desvenlafaxine 100-mg
and 150-mg groups had at least a
50% and 75% reduction in number
of moderate and severe hot flashes
compared to placebo group at
weeks 4 and 12 (P , 0.001 for all
comparisons)
• Desvenlafaxine 100 mg or 150 mg
significantly reduced the average daily
number of nighttime awakenings
compared to placebo at weeks 4
and 12 (P # 0.048 for all
comparisons)
– Placebo: 3.2–2.0 at week 4;
1.8 at week 12
– Desvenlafaxine 100 mg:
3.3–1.5 at week 4; 1.3 at week 12
– Desvenlafaxine 150 mg:
3.1–1.5 at week 4; 1.3 at week 12
• Proportion of patients achieving at
least a 50% or 75% reduction from
baseline in number of hot flashes
– Desvenlafaxine: P = NS at
weeks 4 and 12
– Tibolone: P , 0.001 at
weeks 4 and 12

• Reductions in the daily number of
nighttime awakenings versus placebo
at week 4 were significant for both
desvenlafaxine groups (P , 0.026;
actual reductions not given)
• Reductions in the daily number of
nighttime awakenings versus placebo
at week 12
– Placebo: 3.2–1.8
– Desvenlafaxine 100 mg:
3.9 to 1.5 (P , 0.026)
– Desvenlafaxine 150 mg:
3.5 to 1.1 (P , 0.001)
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Abbreviations: ITT, intention-to-treat; NS, not significant.

– Tibolone: 81% at week 12
(P , 0.001 vs placebo at weeks 4
and 12)
• Average daily hot flush severity score
was not significantly reduced for
desvenlafaxine group at weeks 4 and
12 compared to the placebo group,
but it was significant for tibolone
group at weeks 4 and 12 vs placebo
(P , 0.001 for both comparisons)
• Percentage of women achieving
response (defined as 50% and 75%
reductions from baseline in the number
of moderate and severe hot flushes
at week 12)
– Placebo

Primary results
Primary and
secondary outcomes
Trial design
Clinical
trial

Table 3 (Continued)

Secondary results

Umland and Falconieri

and 150-mg desvenlafaxine groups at weeks 4 and 12 in
both trials conducted by Archer and colleagues (P , 0.001
for all comparisons in one Archer trial;63 P # 0.004 for
all comparisons in the other Archer trial64). Speroff and
colleagues observed a significantly greater proportion of
patients achieving a 75% or greater reduction compared with
the placebo at week 4 in the desvenlafaxine 100-mg, 150-mg,
and 200-mg groups (P = 0.005, P = 0.003, and P = 0.021,
respectively).62 At week 12, only the 100-mg and 200-mg
desvenlafaxine groups had significantly greater proportions
of patients achieving a 75% reduction in the number of hot
flashes (P = 0.003 and P = 0.022, respectively).62 There was
no significant difference between the 50-mg desvenlafaxine
group and placebo with regard to this particular end point
at week 4 or 12. The results and statistics for the 50%
reduction were not reported in the trial. In the trial conducted
by Bouchard and colleagues, there was no significant
difference between the 100-mg desvenlafaxine group and
placebo in the proportion of patients achieving at least a
50% or 75% reduction in the number of hot flashes at either
week 4 or 12, but there was a significant difference between
the 2.5-mg tibolone group and placebo (P , 0.001 for all
comparisons).65
The number of nighttime awakenings attributed to hot
flashes was significantly reduced in the desvenlafaxine
100-mg and 150-mg groups compared to placebo at weeks
4 and 12 in both trials by Archer and colleagues (P , 0.026
and P , 0.001 at week 4 and 12;63 P , 0.04864). Speroff and
colleagues found that this end point was significantly reduced
in the desvenlafaxine 100-mg, 150-mg, and 200-mg groups
compared to placebo at week 12 (P = 0.013, P = 0.034, and
P = 0.043, respectively).62 No significant difference in this
end point was observed between the desvenlafaxine 50-mg
group and placebo at week 12. The results for this end point
at week 4 were not reported in this trial. This end point
was not evaluated in the trial conducted by Bouchard and
colleagues.65

Safety and tolerability
The rates of treatment-emergent adverse effects and
discontinuation were also evaluated in the four desvenlafaxine
clinical trials. The most commonly observed adverse event
in the desvenlafaxine treatment groups in all of these trials
was nausea.
The study by Speroff and colleagues found that women
receiving desvenlafaxine 150 mg or 200 mg experienced
significantly more treatment-emergent adverse events
(P = 0.04 and P = 0.006, respectively) than women in
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the placebo group, while treatment-emergent adverse
events did not differ significantly from placebo in the
desvenlafaxine 50-mg and 100-mg groups.62 The incidence
of nausea in the trial was around 40%–45% depending
on the dose of desvenlafaxine. Discontinuations due to
adverse events occurred at significantly higher rates in
both the 150-mg and 200-mg desvenlafaxine groups (35%
and 40%, respectively) compared with placebo (both
comparisons, P , 0.001), while the rate of discontinuation
in the desvenlafaxine 50-mg and 100-mg groups did not
significantly differ from that associated with placebo.62
In one of the trials by Archer and colleagues, significantly
more desvenlafaxine-treated subjects reported treatmentemergent adverse events during week 1 compared to placebo
(P , 0.05); however, no significant differences between these
two groups were observed at any other time point regarding
this outcome.63 Around 45% of all patients randomized to
desvenlafaxine reported nausea during the trial. Significantly
more patients in the desvenlafaxine groups (26.9% in the
150-mg group; 30.2% in the 200-mg group) discontinued
therapy due to treatment-emergent adverse events compared to
placebo (8.9%; P , 0.001 for either treatment compared to
placebo). In the second trial by Archer and colleagues,
84.1% of the patients treated with desvenlafaxine reported
treatment-emergent adverse events compared with 69.5%
of patients in the placebo group (P , 0.002).64 In this trial
25.5% of women treated with desvenlafaxine reported nausea
during treatment. There were no significant differences in the
rates of discontinuation of treatment for any reason, including
adverse events, between the desvenlafaxine 100-mg (12.7%),
150-mg (16.6%), and placebo groups (9.9%).
The incidence of uterine bleeding was the primary
safety end point in the study conducted by Bouchard
and colleagues.65 This endpoint was chosen because the
comparator drug, tibolone, is a hormonal treatment known to
cause uterine bleeding. The incidence of uterine bleeding was
significantly higher in the tibolone group (23%) compared to
both the desvenlafaxine and placebo groups (12%, P = 0.024,
and 9%, P = 0.001, respectively).65 Treatment-emergent
adverse events were reported among 73.4% of patients in
the 100-mg desvenlafaxine group, 64.5% of patients in the
tibolone group, and 55.9% of patients in the placebo group
(P # 0.006 for placebo vs the tibolone and desvenlafaxine
groups). Nausea was reported in 8.9% and ,4% of patients
in the desvenlafaxine and placebo groups, respectively
(P , 0.001). During the first week of treatment, the rate
of drug discontinuation was significantly higher in the
desvenlafaxine group (11%) than in the tibolone (1.8%)
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or placebo (1.6%) groups (P , 0.001 for desvenlafaxine
vs the tibolone and placebo groups). The rate of drug
discontinuation was not significantly different between the
treatment groups at any other time point.

Discussion
VMS are a disturbing part of menopause for many women
and have a significant impact on QOL. Although hormone
therapy is the most effective treatment for menopause-related
VMS, many women either cannot or do not wish to take this
treatment. Therefore, the availability of effective alternative
therapies for the treatment of VMS is of great importance.
Desvenlafaxine, an SNRI, is one such treatment option for
the treatment of VMS in postmenopausal women.
The desvenlafaxine trials published to date have inconsistent efficacy results. Both trials conducted by Archer and
colleagues found desvenlafaxine to be more beneficial than
placebo in treating VMS in terms of reducing the frequency
of moderate-to-severe hot flashes, reducing the average daily
hot-flash severity score, and reducing nighttime awakenings
at doses of 100 mg and 150 mg.63,64 Speroff and colleagues
also showed desvenlafaxine to be favorable in treating VMS;
however, this trial had some confounding results as not all
of the doses were superior to placebo at all identified time
points.62 Further, while both studies conducted by Archer
and the study conducted by Speroff noted the measurement
of QOL within their research methods, this data has yet to
be made available.62,64 Knowing the link between VMS and
QOL,3,5 the lack of such data is significant. Lastly, Bouchard
and colleagues observed no significant difference between the
desvenlafaxine and placebo groups with regards to the reduction in the number of moderate-to-severe hot flashes, hotflash severity score, or number of nighttime awakenings.65
Several variables may contribute to the difference in
efficacy rates observed in the trials. One important factor
may be dose titration. Only the one study by Archer and
colleagues64 titrated the dose of desvenlafaxine (starting all
patients on 50 mg/day for at least 3 days, then increasing to
100 mg/day, and finally 150 mg/day over 1 week), while
in the other studies patients were started initially on the
dose they were randomized to receive (100 mg, 150 mg,
or 200 mg).62,64,65 Patients not titrated on SNRIs are more
likely to experience adverse effects, in particular nausea.66
As reported, in three of the four clinical trials presented,62,63,65
discontinuation of therapy due to adverse events occurred at
significantly higher rates in the desvenlafaxine-treated groups
compared to the placebo group. No significant difference in
the rate of treatment discontinuation was observed in only one
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of the clinical trials.64 This particular trial was the only one to
titrate the dose of desvenlafaxine over a week. Further, as all
four of these trials used a modified intention-to-treat analysis,
having more women discontinuing therapy due to adverse
effects could make the desvenlafaxine look less desirable
as a treatment option due to safety. In fact, Gallagher and
colleagues conducted a study to look at how titrating the
desvenlafaxine dose affects patient tolerability.66 In this
study, patients were randomized to receive desvenlafaxine for
7 days at the following doses: 100 mg/day (with no titration);
50 mg/day (with no titration); 25 mg/day for 4 days titrated
to 50 mg/day for 3 days; or 25 mg/day (with no titration). All
patients subsequently received desvenlafaxine 100 mg/day
for 15 weeks. Patients titrated to desvenlafaxine 100 mg
experienced significantly less nausea (19%–25%) than the
desvenlafaxine 100-mg group, whose dose was not titrated
(35.2%; P , 0.05). The results of this study suggest that
desvenlafaxine should be titrated to avoid unnecessary
adverse effects that may lead to discontinuation of therapy.
With early discontinuation, the full, potential efficacy of the
medication is not able to be properly evaluated.
Another potential factor contributing to the variability
of the outcomes in these studies is the population of women
included in the analyses. Severity of VMS varies according
to time since the onset of menopause.3,4 Symptoms are most
severe in the 1–4 years surrounding the FMP, with symptoms
improving the farther the woman is from her FMP. While the
inclusion criteria for the clinical trials were generally similar
relative to the frequency and severity of VMS in the included
women,62–65 and the average age of the women was similar,
the age ranges and specifics of the FMP of these women
were quite variable. In both studies by Archer and colleagues,
the average age in each of the trials was 53 years.63,64 In
one of the trials, the ages of the women ranged from 29 to
71 years,64 although the distribution was not reported. The
age distribution was not reported in the other Archer study
either.63 Similarly, in the Speroff et al trial, the average age
was also 53 years; however, the ages ranged from 37 to 78
years old.62 Again, the age distribution was not reported in
this study. Bouchard and colleagues included postmenopausal
women with an average age of 53 years.65 As with the other
desvenlafaxine trials, no age distribution was reported.
Although the average age of women studied in all of the
trials was approximately 53 years, a prominent time for the
occurrence of VMS, the age ranges reported were quite vast,
with women as young as 29 years and as old as 78 years
being included.62–65 In particular, for the women of younger
ages, whether or not their menopause was surgical was not
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reported. It is known that women who enter menopause
due to surgery tend to experience more severe VMS.3 For
reasons such as this, it would be very helpful to know the
percentages of women within the various age ranges in the
trials. Further, it would be helpful to know how many women
were surgically menopausal versus naturally menopausal
in the 1–4 years since their FMP versus 8 or more years
postmenopause. The inclusion of women with widely variable time durations since their FMP may not be prudent to
truly evaluate the effects of medications on VMS. Knowledge
of this information may help to determine whether the symptom improvement observed was secondary to drug treatment
or to the length of time since their FMP. Such variability
in the age ranges included in the studies may have been a
contributor to the variable findings observed.
Additionally, the trials lacked reporting other information
that would be of value in interpreting the trial results and in
making clinical recommendations. Important information not
reported in these trials relates to the proposed risk factors for
VMS. One such determinant, as previously noted, includes
whether or not the women had tried another form of therapy
(hormone therapy, nonhormone therapy, vitamins/herbals,
or even nonpharmacologic) in the past.8 Given the proven
response rates to hormone therapy for VMS,36 women who
had previously been on hormone therapy may have been more
likely to report an inadequate response to desvenlafaxine
in comparison to women who had never tried any kind of
therapy before. Although part of the exclusion criteria in
the trials was that women could not have been taking any
hormone therapy or other medications used for the treatment
of VMS within a certain time period before the trial, there
was no specific mention of herbals and vitamins as part of
this exclusion criteria. As many people do not consider these
entities as “medications,” the reporting regarding taking these
supplements may be inaccurate. If many women were taking
herbals and vitamins to treat hot flashes during the studies,
this would also be considered a confounding variable.
An interesting factor that may have impacted the results
in all of these trials was the placebo effect. In both studies by
Archer et al and the study by Speroff et al, the placebo caused
a reduction in moderate-to-severe daily hot flashes by about
50%.62–64 In the Bouchard et al study, placebo caused a 57.5%
reduction in daily hot flashes.65 The reason for the large placebo
effect seen in these trials is unknown. Perhaps it could be related
to the natural course of the VMS and the age of the women (of
note, this is another instance where the distribution of the ages
of the women included would be useful); that is, perhaps certain
women experienced a natural course of reduction in their VMS
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over time. It may also be an indication of the subjective nature
relative to the perception of VMS.
Other limitations of the trials include the study duration,
the lack of ethnic diversity, and neglecting to evaluate the
presence of VMS risk factors among the study participants.
The efficacy endpoints used in all of the trials were evaluated at 12 weeks, which is a rather short duration. As VMS
are known to last for many years following the FMP,4 longer
trials evaluating the efficacy and safety of desvenlafaxine
over an extended time are warranted. Finally, as previously
mentioned, over 80% of the patients in all of the trials were
Caucasian. This significantly limits the generalizability of
these study findings to other races and ethnicities.

Conclusion
Upon evaluation of the four clinical trials, the results
demonstrate that desvenlafaxine is a viable option for the
treatment of VMS in postmenopausal women. The results
have shown that desvenlafaxine at doses of 100 mg or
higher reduces the frequency of moderate-to-severe hot
flashes and the number of nighttime awakenings. Further,
doses of 100 mg have not been shown to cause significant
side effects, as the incidence of treatment-emergent side
effects with this dose is comparable to that observed with
placebo.62 However, while it is a viable option in comparison
to other therapies, desvenlafaxine cannot be recommended
over the other available treatments. Studies comparing
desvenlafaxine to other available treatment options relative
to efficacy and safety are lacking, with the exception of the
one trial comparing it to tibolone.65 The lack of head-to-head
trials with the nonhormonal treatments, in particular, leave
practitioners with numerous choices, as one medication has
not been shown to be superior. Clinical trials comparing
desvenlafaxine to other nonhormonal treatments are needed
to establish its place relative to these other options. Larger
studies with longer durations, inclusive of more diversity
among subject ethnicity, and with a focus that includes
reporting the impact on overall QOL, are warranted to
evaluate the long-term safety and efficacy of desvenlafaxine
for VMS treatment and improve the generalizability of
the results. Finally, clinical trials evaluating desvenlafaxine
should titrate the dose appropriately to minimize the chance
of treatment discontinuation, and a more distinct study
population should be used that more closely reflects the
typical time frame of when VMS are most severe in relation
to menopause. At this time, desvenlafaxine is a reasonable
option for the treatment of VMS; however, more research is
necessary to define its place in therapy.
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